236 related articles for article (PubMed ID: 34627692)
1. Beneficial effects of glucagon-like peptide 1 receptor agonists on glucose control, cardiovascular risk profile, and non-alcoholic fatty liver disease. An expert opinion of the Italian diabetes society.
Napoli R; Avogaro A; Formoso G; Piro S; Purrello F; Targher G; Consoli A
Nutr Metab Cardiovasc Dis; 2021 Nov; 31(12):3257-3270. PubMed ID: 34627692
[TBL] [Abstract][Full Text] [Related]
2. Treatment Strategy for Type 2 Diabetes with Obesity: Focus on Glucagon-like Peptide-1 Receptor Agonists.
Ji Q
Clin Ther; 2017 Jun; 39(6):1244-1264. PubMed ID: 28526416
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular safety and benefits of GLP-1 receptor agonists.
Dalsgaard NB; Brønden A; Vilsbøll T; Knop FK
Expert Opin Drug Saf; 2017 Mar; 16(3):351-363. PubMed ID: 28102093
[TBL] [Abstract][Full Text] [Related]
4. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
[TBL] [Abstract][Full Text] [Related]
5. Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease-Current Evidence.
Muzurović EM; Volčanšek Š; Tomšić KZ; Janež A; Mikhailidis DP; Rizzo M; Mantzoros CS
J Cardiovasc Pharmacol Ther; 2022; 27():10742484221146371. PubMed ID: 36546652
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
Zhu Y; Xu J; Zhang D; Mu X; Shi Y; Chen S; Wu Z; Li S
Front Endocrinol (Lausanne); 2021; 12():769069. PubMed ID: 34956080
[TBL] [Abstract][Full Text] [Related]
7. Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation.
Wang XC; Gusdon AM; Liu H; Qu S
World J Gastroenterol; 2014 Oct; 20(40):14821-30. PubMed ID: 25356042
[TBL] [Abstract][Full Text] [Related]
8. Review of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus in patients with chronic kidney disease and their renal effects.
Sloan LA
J Diabetes; 2019 Dec; 11(12):938-948. PubMed ID: 31318152
[TBL] [Abstract][Full Text] [Related]
9. Management of type 2 diabetes for prevention of cardiovascular disease. An expert opinion of the Italian Diabetes Society.
Napoli R; Formoso G; Piro S; Targher G; Consoli A; Purrello F
Nutr Metab Cardiovasc Dis; 2020 Oct; 30(11):1926-1936. PubMed ID: 32928628
[TBL] [Abstract][Full Text] [Related]
10. Glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: An update.
Sofogianni A; Filippidis A; Chrysavgis L; Tziomalos K; Cholongitas E
World J Hepatol; 2020 Aug; 12(8):493-505. PubMed ID: 32952876
[TBL] [Abstract][Full Text] [Related]
11. GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data.
Sposito AC; Berwanger O; de Carvalho LSF; Saraiva JFK
Cardiovasc Diabetol; 2018 Dec; 17(1):157. PubMed ID: 30545359
[TBL] [Abstract][Full Text] [Related]
12. GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential.
Ma X; Liu Z; Ilyas I; Little PJ; Kamato D; Sahebka A; Chen Z; Luo S; Zheng X; Weng J; Xu S
Int J Biol Sci; 2021; 17(8):2050-2068. PubMed ID: 34131405
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: A systematic review and meta-analysis.
Dong Y; Lv Q; Li S; Wu Y; Li L; Li J; Zhang F; Sun X; Tong N
Clin Res Hepatol Gastroenterol; 2017 Jun; 41(3):284-295. PubMed ID: 28065744
[TBL] [Abstract][Full Text] [Related]
14. Review article: role of glucagon-like peptide-1 receptor agonists in non-alcoholic steatohepatitis, obesity and diabetes-what hepatologists need to know.
Barritt AS; Marshman E; Noureddin M
Aliment Pharmacol Ther; 2022 Apr; 55(8):944-959. PubMed ID: 35266164
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic Mechanisms and Clinical Effects of Glucagon-like Peptide 1 Receptor Agonists in Nonalcoholic Fatty Liver Disease.
Lee HA; Kim HY
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298276
[TBL] [Abstract][Full Text] [Related]
16. How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials.
Lee MMY; Petrie MC; McMurray JJV; Sattar N
Arterioscler Thromb Vasc Biol; 2020 Mar; 40(3):506-522. PubMed ID: 31996025
[TBL] [Abstract][Full Text] [Related]
17. Long-acting GLP-1 receptor agonists: Findings and implications of cardiovascular outcomes trials.
Urquhart S; Willis S
JAAPA; 2020 Aug; 33(S8 Suppl 1):19-30. PubMed ID: 32756221
[TBL] [Abstract][Full Text] [Related]
18. Glucose control independent mechanisms involved in the cardiovascular benefits of glucagon-like peptide-1 receptor agonists.
Wu Q; Li D; Huang C; Zhang G; Wang Z; Liu J; Yu H; Song B; Zhang N; Li B; Chu X
Biomed Pharmacother; 2022 Sep; 153():113517. PubMed ID: 36076602
[TBL] [Abstract][Full Text] [Related]
19. Lower risk of death and cardiovascular events in patients with diabetes initiating glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors: A real-world study in two Italian cohorts.
Baviera M; Genovese S; Lepore V; Colacioppo P; Robusto F; Tettamanti M; D'Ettorre A; Avanzini F; Fortino I; Nicolucci A; Roncaglioni MC; Giorgino F
Diabetes Obes Metab; 2021 Jul; 23(7):1484-1495. PubMed ID: 33606897
[TBL] [Abstract][Full Text] [Related]
20. Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with Type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of randomized controlled trials.
Marsico F; Paolillo S; Gargiulo P; Bruzzese D; Dell'Aversana S; Esposito I; Renga F; Esposito L; Marciano C; Dellegrottaglie S; Iesu I; Perrone Filardi P
Eur Heart J; 2020 Sep; 41(35):3346-3358. PubMed ID: 32077924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
